Related Experiment Video
Updated: Sep 30, 2026
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
Anti-SARS-CoV-2 Monoclonal Antibodies in Pediatrics: Statewide Experience in Rhode Island
Osama Ibrahim1, Winston McCormick2, Kristen Ferlisi3
1Division of Pediatric Infectious Diseases, Department of Pediatrics, Hasbro Children's Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Insights
Monoclonal antibody infusions were well tolerated in high-risk pediatric COVID-19 patients. This study found few adverse events and hospitalizations, suggesting a safe treatment option for children.
Area of Science:
- Pediatric infectious diseases
- Immunology
- Pharmacology
Background:
- Pediatric COVID-19 infections present significant morbidity and mortality.
- Limited oral treatment options exist for children under 12.
- Monoclonal antibodies are a potential treatment modality, but pediatric data is scarce.
Purpose of the Study:
- To assess the efficacy and safety of anti-SARS-CoV-2 monoclonal antibodies in pediatric patients.
- To report patient characteristics, side effects, and 30-day post-treatment outcomes.
- To provide the largest case series on monoclonal antibody use in this population.
Main Methods:
- Retrospective case series design.
- Inclusion of high-risk pediatric COVID-19 patients receiving monoclonal antibody infusions.
- Data collection from January 2021 to January 2022 at a tertiary care center.
Main Results:
- 108 pediatric patients were included in the study.
- Seven patients (6.5%) experienced infusion-related reactions; no other adverse events were reported.
- Three patients sought emergency care for worsening symptoms, and one was admitted to the pediatric ICU for respiratory decline within 30 days.
Conclusions:
- Monoclonal antibody infusions were generally well-tolerated in the studied pediatric population.
- The findings suggest a favorable safety profile for monoclonal antibodies in treating pediatric COVID-19.
- This case series contributes valuable data on the use of monoclonal antibodies in children.
Background:
The pediatric population has suffered COVID-19 infections with measurable morbidity and mortality. Without oral options in those less than 12 years of age, practical treatment in this rapidly evolving disease is necessary. One treatment modality is monoclonal antibodies. Limited information describes the efficacy and safety of anti-SARS-CoV-2 monoclonal antibodies in pediatrics. This is the largest case series addressing efficacy and safety of monoclonal antibodies in this population.
Objective:
To report patient characteristics, side effects encountered, and hospital admissions or emergency department visits within 30 days following treatment.
Design:
This retrospective case series includes high-risk pediatric COVID-19 patients who received monoclonal antibody infusions in a tertiary care center as outpatients between January 2021 and January 2022.
Outcomes:
There were 108 patients included with seven patients (6.5%) having infusion-related reactions with no other adverse events reported. Following the monoclonal treatment, three patients presented to the emergency department for worsening symptoms, and one patient was admitted to the pediatric ICU for worsening respiratory status. No other admissions or emergency department visits were reported in the one month following the infusion.
Conclusions:
In this case series study, monoclonal antibody infusions were well tolerated.
